Published summary: 2026-03-07
Where the evidence converges
A machine learning model using just five factors — sex, delinquency, and three personality traits — predicted cannabis use disorder within 5 years of first use, validated across three datasets
Moderate evidence · 10 studies
Based on limited number of strong-evidence studies.
Nearly 1
Moderate evidence · 10 studies
Based on limited number of strong-evidence studies.
Where questions remain
Among 420 teen cannabis users, using multiple product types (flower, concentrates, edibles) was the strongest predictor of cannabis use disorder at 6 months — stronger than any single product type
Moderate evidence · 6 studies
Southern California specific — may not generalize to regions with different cannabis markets. Self-reported use and CUD screening (not diagnosis). Short 6-month follow-up. Cannot determine if poly-pro
Analysis of a cannabis cessation app revealed distinct user profiles: coping-motivated users showed the most problematic use, suggesting digital interventions should personalize content based on why people use cannabis
Moderate evidence · 6 studies
App users are self-selected and may not represent all cannabis users. Cross-sectional — cannot track whether app use led to behavior change. Cluster analysis is exploratory. Specific to one app in a S
Researchers successfully adapted tobacco dependence measures to cannabis, creating a reliable 15-item scale that enables direct comparison of dependence across both substances for the first time
Moderate evidence · 6 studies
Single sample from a longitudinal study — may not represent all cannabis users. Adaptation from tobacco measures may miss cannabis-specific dependence features. Self-report only. Cross-sectional valid
National survey data showing psilocybin and LSD use associated with approximately double the risk of cannabis use disorder, complicating therapeutic psychedelic narratives
Moderate evidence · 6 studies
Cross-sectional design — people who use psychedelics may simply be more likely to use cannabis heavily for reasons unrelated to the psychedelic experience. Cannot distinguish therapeutic from recreati
Research gaps
- Only 0 randomized controlled trials exist out of 30 studies — most evidence is observational or from reviews.
- Sex-specific differences in this area remain understudied.
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Why There's Still No FDA-Approved Medication for Cannabis Addiction
Cannabis use disorder affects millions but has zero FDA-approved treatments — understanding why the pipeline is stuck is essential for breaking through to effective medications.
Using Cannabis in More Ways Dramatically Increases Risk of Addiction and Harm
Cannabis product diversification means young people can now use in many ways — this study shows the number of modes is an independent risk marker, not just a proxy for more frequent use.
The Genetics of Trying Cannabis Are Different from the Genetics of Cannabis Addiction
The genetic distinction between trying cannabis and developing addiction is crucial — it means different people need different prevention approaches, and trying cannabis alone isn't a genetic pathway to addiction.
Up to 1 in 5 People With Anxiety Disorders Also Have Cannabis Use Disorder
As cannabis becomes more accessible, understanding who is most vulnerable to problematic use is critical. People with anxiety disorders may use cannabis to cope but are at meaningful risk of developing dependence, creating a cycle that worsens both conditions.
Cannabis Use Disorder Rising Dramatically Among Aging Veterans with HIV
As people with HIV live longer on antiretroviral therapy, rising cannabis use disorder in this aging population is concerning because cannabis can interact with many prescription medications these patients take.
Cannabis Use Disorder Is Now the World's Most Prevalent Drug Use Disorder
Published in Nature Medicine, this comprehensive global analysis reveals that cannabis use disorder has become the world's most common drug use disorder, with legalization policies associated with higher rates across all substance categories.
How the research developed
2020–present
30 studies published. Includes 10 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 30 peer-reviewed studies: 11 observational studies (37%), 2 reviews (7%), 17 other study types (57%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.